NHLBI POLICY ON COMPETING CONTINUATION (TYPE 2) SUBMISSIONS
National Heart, Lung, and Blood
Institute
National Institutes of Health
May 2006
Instructions for competing continuation applications are contained in the PHS
398 application kit (rev. 5/2001). For completion of Item 6 on the Face Page,
“Dates of Proposed Period of Support,” applicants are referred to
the PHS receipt, review, and award schedule (
http://grants1.nih.gov/grants/funding/phs398/instructions2/p1_submission_dates.htm#Table2_Cycles ),
which lists the earliest possible award start dates associated with the standard
application receipt dates. The Form 398 instructions also direct applicants for
competing continuations to “choose a beginning date immediately following
the termination date of the current period of support.”
The NHLBI is aware of the desire of investigators to avoid interruptions in
support and to ensure that sufficient time is available to them to prepare and
submit a revised application if necessary. Many investigators use their authority
for a one-time, automatic no-cost extension to prevent a hiatus in support.
Others choose to submit a competing continuation application early. Both of
these practices are acceptable. However, all applicants should be aware that:
- A competing continuation application will not be awarded before the end
of the last noncompeting continuation period of the previous competitive project
period. Decisions regarding funding for such applications are made in accordance
with the funding plan of the NHLBI for the fiscal year of their requested
start date or the fiscal year of their earliest possible start date, whichever
occurs later.
- The NHLBI is not required to meet a requested start date. The PHS 398 application
states “NIH awarding components may not always be able to honor the
requested start date. No commitments or obligations should be made until confirmation
of the actual start date by the awarding component.”
|
HOME
Department of Health
and Human Services
National
Institutes of Health
National Heart, Lung, and Blood
Institute